Lobenzarit disodium (CCA) inhibits in vitro immunoglobulin production via direct interaction with B lymphocytes.
The regulatory effects of lobenzarit disodium (CCA), a therapeutic agent for treating rheumatoid arthritis (RA), on polyclonal immunoglobulin production by human lymphocytes were investigated in vitro. CCA inhibited the production of immunoglobulin in all the classes examined at a clinically relevant concentration. Moreover, it inhibited the immunoglobulin production as well as lymphocyte proliferation even when purified B lymphocytes preactivated by Staphylococcus aureus COWAN I were cultured with recombinant lymphokines such as IL2 and IL6. These results suggest that CCA acts directly on B lymphocytes. The analysis at each of two different stages of B lymphocyte activation lineage, i.e., the primary activation stage and a stage of proliferation and differentiation to antibody secreting cells, has indicated that CCA inhibits the proliferation-differentiation stage of B lymphocytes. CCA does not inhibit B lymphocytes at the primary activation stage; actually, it augments them, resulting in the subsequent enhancement of immunoglobulin production.
Takeda
Y
Y
Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan.
Urakawa
K
K
Sakamoto
A
A
Nakano
T
T
Sugawara
Y
Y
Ohsugi
Y
Y
Morita
M
M
Kasahara
T
T
D000328:Adult; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D002648:Child; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D062367:ortho-Aminobenzoates / Q000494:pharmacology*
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D062367:ortho-Aminobenzoates; C015735:lobenzarit